Following the FDA ODD, European designation underscores ICT01’s potential as a ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...